<DOC>
	<DOCNO>NCT02292446</DOCNO>
	<brief_summary>The purpose open-label , single arm , multi-center Expanded Treatment Protocol ( ETP ) provide early access ruxolitinib evaluate safety information patient PV , HU resistant intolerant standard treatment option , qualify another clinical study PV .</brief_summary>
	<brief_title>Expanded Treatment Protocol ( ETP ) Ruxolitinib Patients With Polycythemia Vera Who Are Hydroxyurea Resistant Intolerant Whom Treatment Alternatives Are Available .</brief_title>
	<detailed_description />
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>•Confirmed diagnosis PV accord 2008 World Health Organization criterion , palpable spleen , Resistant intolerant hydroxyurea , ECOG performance status 0 , 1 2 ; access comparable satisfactory alternative treatment •Inadequate liver renal function , Significant bacterial , fungal , parasitic , viral infection require treatment , Active malignancy within past 5 year , except treated cervical intraepithelial neoplasia , basal cell carcinoma skin , squamous cell carcinoma skin , evidence recurrence past 3 years. , Women pregnant nursing . Other inclusion/exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Polycythemia Vera</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Myeloproliferative Disorders</keyword>
	<keyword>INC424</keyword>
	<keyword>Ruxolitinib</keyword>
</DOC>